Mechanisms of recurrence of Ta/T1 bladder cancer
Open Access
- 1 September 2010
- journal article
- Published by Royal College of Surgeons of England in The Annals of The Royal College of Surgeons of England
- Vol. 92 (6), 519-524
- https://doi.org/10.1308/003588410x12664192076935
Abstract
INTRODUCTION Bladder cancer recurrence occurs via four mechanisms - incomplete resection, tumour cell re-implantation, growth of microscopic tumours, and new tumour formation. The first two mechanisms are influenced by clinicians before and immediately after resection; the remaining mechanisms have the potential to be influenced by chemopreventive agents. However, the relative importance and timing of these mechanisms is currently unknown. Our objective was to postulate the incidence and timing of these mechanisms by investigating the location of bladder cancer recurrences over time. PATIENTS AND METHODS The topographical locations of tumours and their recurrences were analysed retrospectively for 169 patients newly-diagnosed with Ta/T1 bladder cancer, with median follow-up of 33.8 months. Tumours were assigned to one or more of six bladder sectors, and time to recurrence and location of recurrences were recorded. RESULTS Median time to first tumour recurrence was 40 months. Median times between subsequent recurrences were 6.6, 7.9, 8.0 and 6.6 months for recurrences 1 to 2, 2 to 3, 3 to 4, and 4 to 5, respectively. The risk of first tumour recurrence in any given bladder sector increased by nearly 4-fold if the primary tumour was resected from that sector (P < 0.001); this association was not significant for subsequent recurrences. The proportion of tumour recurrences in multiple bladder sectors increased from 13% for the first recurrence to 100% for recurrence seven onwards. CONCLUSIONS First tumour recurrence appears different to subsequent recurrences; incomplete resection and tumour cell re-implantation may dominate at this time-point. Only later does genuine new tumour formation appear to increase in importance. This has important implications for clinical trials, especially those involving chemopreventive agents.This publication has 35 references indexed in Scilit:
- The West Midlands Bladder Cancer Prognosis Programme: rationale and designBJU International, 2010
- Narrow‐band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladderBJU International, 2007
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006
- Effect of Routine Repeat Transurethral Resection for Superficial Bladder Cancer: A Long-term Observational StudyJournal of Urology, 2003
- Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tractOncogene, 2001
- FLUORESCENCE ENDOSCOPY WITH 5-AMINOLEVULINIC ACID REDUCES EARLY RECURRENCE RATE IN SUPERFICIAL BLADDER CANCERJournal of Urology, 2001
- Significance of Bladder Biopsies in Ta,T1 Bladder Tumors: A Report from the EORTC Genito-Urinary Tract Cancer Cooperative GroupEuropean Urology, 1999
- The Effect of Intravesical Mitomycin C on Recurrence of Newly Diagnosed Superficial Bladder Cancer: A Further Report with 7 Years of FollowupJournal of Urology, 1996
- Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at DiagnosisMedical Care, 1995
- Mosaicism in Human Epithelium: Macroscopic Monoclonal Patches Cover the UrotheliumJournal of Urology, 1995